The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Bone health in cancer: ESMO Clinical Practice Guidelines
Open accessAbstract
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.•Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.•The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Self-citationStopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Self-citationDenosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citationEastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Self-citationCummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.-E. B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 734
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Self-citation
Research works printed but not linked: 7
- Dennis, 2012, Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer, J Clin Oncol, 30, 519, 10.1200/JCO.2011.36.5791 · doi:10.1200/jco.2011.36.5791
- Rich, 2018, Update of the systematic review of palliative radiation therapy fractionation for bone metastases, Radiother Oncol, 126, 547, 10.1016/j.radonc.2018.01.003 · doi:10.1016/j.radonc.2018.01.003
- Willeumier, 2016, Treatment of pathological fractures of the long bones, EFORT Open Rev, 1, 136, 10.1302/2058-5241.1.000008 · doi:10.1302/2058-5241.1.000008
- Coleman, 2013, Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features – an exploratory analysis of placebo-controlled trials, J Bone Oncol, 2, 70
- Otto, 2018, Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases, Cancer Treat Rev, 69, 177, 10.1016/j.ctrv.2018.06.007 · doi:10.1016/j.ctrv.2018.06.007
- Saad, 2012, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases, Ann Oncol, 23, 1341, 10.1093/annonc/mdr435 · doi:10.1093/annonc/mdr435
- Sprave, 2018, Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy, Radiother Oncol, 128, 274, 10.1016/j.radonc.2018.04.030 · doi:10.1016/j.radonc.2018.04.030
Cited by
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Volume 31 - Issue 12 - 2020 The ABC panel decided to endorse the ESMO Clinical Practice Guideline (CPG) related to the use of bone-targeted agents (bisphosphonate, denosumab), which replace all previous statements regarding this subject.(99) Leptomeningeal disease (LMD) is a rare complication of breast cancer with a 5…”
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Metadata
- Authors
- Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., & Jordan, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 31
- Issue
- 12
- Pages
- 1650-1663
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3048934302
- Cited by
- 549
- References
- 38
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- ESMO
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone health in cancer: ESMO Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1016/j.annonc.2020.07.019
- The paper
- Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., & Jordan, K. (2020). Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.07.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
